Taxotere®

DRUG5 trials

Sponsors

University Hospital, Limoges, Centre Antoine Lacassagne, Pfizer, Qilu Pharmaceutical (Hainan) Co., Ltd., CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Conditions

Advanced Breast CancerAdvanced Solid TumorsCarcinoma, Non-Small-Cell LungEarly Breast CancerProstatic Neoplasms

Phase 1

A Study of QLM2011 in Subjects With Advanced Solid Tumors

Not yet recruitingNCT06925659

Qilu Pharmaceutical (Hainan) Co., Ltd.Advanced Solid Tumors

Start: 2025-05-31End: 2027-02-28Target: 172Updated: 2025-04-17

Phase 2

Metformin-Docetaxel Association in Metastatic Hormone-refractory Prostate Cancer

CompletedNCT01796028

Centre Antoine LacassagneProstatic Neoplasms

Start: 2013-01-31End: 2018-05-31Updated: 2018-06-06

A Study Comparing the Efficacy and Safety of HB1801 With Taxotere® in Advanced Breast Cancer

Not yet recruitingNCT07083505

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Advanced Breast Cancer

Start: 2025-08-15End: 2026-12-31Target: 60Updated: 2025-07-24

Phase 3

Pharmaco-economic Study of a Second Line Treatment in Advanced Non Small Cell Lung Cancer

CompletedNCT00284778

University Hospital, LimogesCarcinoma, Non-Small-Cell Lung

Start: 2006-02-28End: 2009-12-31Updated: 2025-07-24

A Study Of PF-05280014 Or Trastuzumab Plus Taxotere® And Carboplatin In HER2 Positive Breast Cancer In The Neoadjuvant Setting (REFLECTIONS B327-04)

CompletedNCT02187744

PfizerEarly Breast Cancer

Start: 2014-09-23End: 2016-03-09Updated: 2019-01-08

Related Papers

Long-Term Safety and Effectiveness of PF-05280014 (a Trastuzumab Biosimilar) Treatment in Patients with HER2-Positive Metastatic Breast Cancer: Updated Results of a Randomized, Double-Blind Study

BioDrugs2022-01-0112 citations

TAXOMET: A French prospective multicenter randomized controlled phase II study comparing docetaxel plus metformin versus docetaxel plus placebo in mCRPC.

Journal of Clinical Oncology2019-05-209 citations

Development of PF-05280014, a potential biosimilar to trastuzumab.

Journal of Clinical Oncology2015-05-203 citations